Adam Lee

1.0k total citations · 1 hit paper
32 papers, 359 citations indexed

About

Adam Lee is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Infectious Diseases. According to data from OpenAlex, Adam Lee has authored 32 papers receiving a total of 359 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 5 papers in Infectious Diseases. Recurrent topics in Adam Lee's work include Lung Cancer Treatments and Mutations (10 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Colorectal Cancer Treatments and Studies (4 papers). Adam Lee is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Colorectal Cancer Treatments and Studies (4 papers). Adam Lee collaborates with scholars based in United States, United Kingdom and Germany. Adam Lee's co-authors include Adi V. Gundlapalli, Adam MacNeil, Kristie E.N. Clarke, Yangyang Deng, Ronaldo Iachan, Aron J. Hall, Jefferson M. Jones, Robert B. Diasio, Jeanne Fourie and Hany Ezzeldin and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Adam Lee

26 papers receiving 343 citations

Hit Papers

Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies... 2022 2026 2023 2024 2022 50 100 150

Peers

Adam Lee
Comparison fields: 5 of 64
  • Infectious Diseases 157
  • Oncology 92
  • Pulmonary and Respiratory Medicine 85
  • Modeling and Simulation 36
  • Health 33
Anwar A. Sayed Saudi Arabia
Héctor Alexander Velásquez García Canada
Ibrahim Alghamdi Saudi Arabia
Gordon Hay United Kingdom
Xingguang Lin China
Shengxia Yin China
Om Prakash India
Xiucui Han China
Philippos Edimiris Germany
Hajar Abbasi Iran
Anwar A. Sayed Saudi Arabia View profile →
Citations per field, relative to Adam Lee
Adam Lee · 1×
Citations per year, relative to Adam Lee
Adam Lee · 1×

Countries citing papers authored by Adam Lee

Since Specialization
Citations

This map shows the geographic impact of Adam Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam Lee more than expected).

Fields of papers citing papers by Adam Lee

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adam Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam Lee. The network helps show where Adam Lee may publish in the future.

Co-authorship network of co-authors of Adam Lee

This figure shows the co-authorship network connecting the top 25 collaborators of Adam Lee. A scholar is included among the top collaborators of Adam Lee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adam Lee. Adam Lee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Title Journal Authors Indexed citations
1 Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis Frontiers in Oncology C. Chouaïd, D. Debieuvre et al. 1
2 Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic NSCLC Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1 Journal of Thoracic Oncology Solange Peters, Meredith M. Regan et al. 0
3 Population-Adjusted Indirect Treatment Comparisons of Repotrectinib Among Patients with ROS1+ NSCLC Cancers Jürgen Wolf, Sarah Goring et al. 0
4 Treatment-Switching Adjustment of Overall Survival in CheckMate 227 Part 1 Evaluating First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy for Metastatic Nonsmall Cell Lung Cancer Clinical Lung Cancer Martin Reck, Luis Paz‐Ares et al. 0
5 Cost-Effectiveness of Nivolumab Plus Ipilimumab versus Chemotherapy for Previously Untreated Metastatic NSCLC Using Mixture-Cure Survival Analysis Based on CheckMate 227 5-Year Data PharmacoEconomics - Open Alison Griffiths, Yong Yuan et al. 0
6 Treatment patterns and outcomes of patients with metastatic non-small cell lung cancer in five European countries: a real-world evidence survey BMC Cancer Adam Lee, Laura J. Eccles et al. 7
7 Galacto-oligosaccharides fed during gestation increase Rotavirus A specific antibodies in sow colostrum, modulate the microbiome, and reduce infectivity in neonatal piglets in a commercial farm setting Frontiers in Veterinary Science Adam Lee, Lu Liang et al. 5
8 COVID-19 data driven planning: The SouthEast Texas approach Journal of Emergency Management Adam Lee et al. 0
9 Estimated SARS-CoV-2 antibody seroprevalence trends and relationship to reported case prevalence from a repeated, cross-sectional study in the 50 states and the District of Columbia, United States—October 25, 2020–February 26, 2022 The Lancet Regional Health - Americas Ryan E. Wiegand, Yangyang Deng et al. 29
10 Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States Journal of Medical Economics Mohammad A. Chaudhary, Yong Yuan et al. 5
11 Treatment patterns for advanced non-small cell lung cancer in the US: A systematic review of observational studies Cancer Treatment and Research Communications Adam Lee, Yong Yuan et al. 5
12 Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung Cancer: A systematic review and meta-analysis Lung Cancer Sarah Goring, N. Varol et al. 7
13 Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: retrospective analysis from Leeds Cancer Centre BMC Cancer Chris Twelves, Sue Cheeseman et al. 11
14 Changes to the sample design and weighting methods of a public health surveillance system to also include persons not receiving HIV medical care PLoS ONE Christopher H. Johnson, Linda Beer et al. 4
15 Cost-effectiveness Analysis of Ribociclib plus Letrozole versus Palbociclib plus Letrozole in the United Kingdom Journal of health economics and outcomes research Gaurav Suri, David Chandiwana et al. 1
16 Cost-effectiveness Analysis of Ribociclib plus Letrozole versus Palbociclib plus Letrozole in the United Kingdom Journal of health economics and outcomes research Gaurav Suri, David Chandiwana et al. 12
17 Juvenile Polyposis coli in a 9 year old boy Adam Lee, Judy Ho et al. 1
18 Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer International Journal of Molecular Sciences Moritz Binder, Ben Zhang et al. 19
19 Genotypic characterization of dihydropyrimidinase andβ-ureidopropionase in an African American and Caucasian population: New potential pharmacogenetic markers for 5-fluorouracil toxicity in the African American population Cancer Epidemiology and Prevention Biomarkers Hany Ezzeldin, Lori K. Mattison et al. 1
20 Isodicentric Philadelphia chromosomes in imatinib mesylate (Gleevec)-resistant patients Cancer Genetics and Cytogenetics Jane L. Liesveld, M. Anwar Iqbal et al. 7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026